Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The ITCA 650 enables subcutaneous delivery of exenatide using a match-sized osmotic pump placed under the skin in an in-office procedure.
With the NDA submission, the Boston-based company triggered a 3rd, $100 million milestone payment from the $300 million royalty financing put in place in the 2nd quarter of 2015. The milestone payment adds to the $215 million Intarcia raised in September.
Get the full story at our sister site, Drug Delivery Business News
The post Intarcia seeks FDA nod for Medici drug delivery system appeared first on MassDevice.
from MassDevice http://ift.tt/2gdePNN
Cap comentari:
Publica un comentari a l'entrada